Stocks · News reference
Pomerantz LLP has initiated an investigation into EyePoint, Inc. regarding potential securities fraud or unlawful business practices following recent clinical trial results.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
EyePoint, Inc. announced it will host a conference call and live webcast on November 12, 2026, to discuss its third quarter 2026 financial results and recent corporate developments.
JonesTrading analyst Debanjana Chatterjee has downgraded EyePoint Pharmaceuticals (NASDAQ: EYPT) from a previous rating to a Hold rating.
EyePoint Pharmaceuticals is cutting its workforce by 50% and ending its late-stage clinical trials for wet age-related macular degeneration (AMD) following a second clinical trial failure.
Multiple financial institutions, including JPMorgan, Mizuho Securities, and Guggenheim, downgraded EyePoint Pharmaceuticals' stock rating following the company's recent clinical trial failure.
Laidlaw & Co. analyst Yale Jen downgrades EyePoint (NASDAQ:EYPT) from Buy to Hold.